Only a small percentage of cancer patients receive genetic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. At Canexia Health, we pair the latest advances in oncology with machine learning to provide oncology professionals with the insights needed to inform targeted treatment decisions.
Together, we’re making precision oncology more accessible.
Our expertise in genomics-based cancer assays, bioinformatics, and machine learning runs deep thanks to the strong foundation laid by our scientific and medical leaders, Drs. Samuel Aparicio, David Huntsman, and Sohrab Shah.
Our founders have earned international recognition for their work in cancer research. Collectively, they’ve published more than 400 peer-reviewed articles in the fields of cancer genomics, diagnosis, and bioinformatics, including in the New England Journal of Medicine, Science, Nature and Nature Genetics.
At Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Visit our Investor Relations page for information for stockholders, potential investors, and financial analyst.
Chief Executive Officer
Chief Scientific Officer
Chief Medical Officer
Chief Informatics Officer
VP Clinical Operations and Customer Success
Senior Vice President, Business Development
VP, Marketing & Product Management